



Please Fax Completed Form To: 888-898-9113

Please Send a Copy of The Patient's Insurance Cards (Front & Back)
Please Send a Copy of The Patient's Up-to-Date Clinical Notes

PATIENT INFORMATION (Complete or Fax Existing Chart)		t) PRESCRIBER INFORMATION	PRESCRIBER INFORMATION		
Name:	DOB:	Prescriber Name:	Prescriber Name:		
Address:		State License:	State License:		
City, State, Zip:			NPI #: Tax ID:		
Phone: Alt. Phone:			Address:		
Email: SS#:			City, State, Zip:		
Gender: ☐ M ☐ F Weight:	(lbs) Ht:		Phone: Fax:		
Allergies:		Office Contact:	Phone:		
INSURANCE INFORMATION – AND – Send a copy of the patient's prescription/insurance cards (front & back)					
Primary Insurance:		Secondary Insurance (If Applicable):			
Plan #:		Plan #:	Plan #:		
Group #:		Group #:	Group #:		
RX Card (PBM):			RX Card (PBM):		
BIN:	PCN:	BIN: PCN:			
CLINICAL INFORMATION					
☐ G36.0 Neuromyelitis optica	☐ Other ICD-10/Diagnosis:				
Hepatitis B vaccination: ☐ Yes ☐ No Date: Hepatitis B screening: ☐ Positive ☐ Negative Date:					
HB core antibody HBcAB+ results: Positive Negative Date: Tuberculosis Screening: Positive Negative Date:					
		two loading dosing completed: ☐ Yes ☐ No			
·	t be administered in a controlled setting	• • •			
UPLIZNA® ORDERS					
Prescription type: ☐ New start	☐ Restart ☐ Continued therapy Total Doses Received: Date of Last Injection/Infusion:				
Medication		Dose/Frequency	Qty/Refills		
Uplizna® (inebilizumab injection)	☐ Initial Dose: ☐ 300mg IV infusion over 90 minutes at day 1 and 2 weeks later				
	Other:		Quantity:		
	☐ Maintenance Dose: ☐ 300mg IV infusion over 90 minutes every 6 months		Refills:		
	□ Other:				
Pre-Medication	Dose/Strength	Directions	Directions		
☐ Acetaminophen	□ 500mg	\square Take 1-2 tablets PO prior to infusion or post-infusio	e 1-2 tablets PO prior to infusion or post-infusion as directed		
☐ Diphenhydramine	☐ 25mg IV/PO	☐ Take 1 tablet PO prior to infusion or as directed OR	e 1 tablet PO prior to infusion or as directed OR		
	☐ 50mg IV/PO	\Box Inject contents of 1 vial IV prior to infusion or as dir	ct contents of 1 vial IV prior to infusion or as directed		
☐ Methylprednisolone	□ 40mg □ 100mg	☐ Inject contents of 1 vial IV prior to infusion or as dir	ct contents of 1 vial IV prior to infusion or as directed		
	☐ 125mg	\Box Other: Inject 100mg IV 30 minutes prior to infusion	er: Inject 100mg IV 30 minutes prior to infusion		
INFUSION REACTION ORDERS					
Mild reaction protocol:					
☐ Diphenhydramine 25mg IV, one time, for pruritus.					
If symptoms worsen, see orders for moderate to severe reactions.					
Moderate reaction protocol: ☑ Acetaminophen 650mg PO, one time, for pyrexia or rigors					

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.





Please Fax Completed Form To: 888-898-9113

Please Send a Copy of The Patient's Insurance Cards (Front & Back)
Please Send a Copy of The Patient's Up-to-Date Clinical Notes

☑ Diphenhydramine 50mg IV, one time, for pruri	tus or urticaria					
☑ Methylprednisolone 125mg IV, one time, for respiratory or neurologic symptoms						
If symptoms worsen, see interventions for severe reactions						
Severe reaction protocol: (Call 911 if initiated):						
☑ Titrate oxygen via continuous flow per nasal cannula or face mask to maintain spO2 of greater than ninety-five percent (>95%)						
☑ Diphenhydramine 50mg IV,one time, for respir	ratory symptoms, edema, o	or anaphylaxis				
	espiratory symptoms, eder	na, or anaphylaxis				
Sodium Chloride 0.9% 500mL IV over 30-60 mi	n, one time, for cardiovasc	ular symptoms				
			1 in 5-15 minutes if symptoms are not resolved or			
worsen						
FLUSHING & LOCKING ORDERS						
Flushing Protocol (>66lbs/33kg)						
PIV and Midline:		Implanted Port, PICC, Tunneled Catheter, and Non-tunneled Catheter:				
oxtimes 0.9% Sodium Chloride 2-5mL IV flush before an	d after each infusion	☑ 0.9% Sodium Chloride 5mL IV flush before infusion/lab draw and 10mL				
		IV flush after infusion/lab draw				
Locking Protocol (>66lbs/33kg)						
PIV and Midline:	PICC:		Implanted Port, Tunneled Catheter, and Non-			
☑ Heparin Sodium 10 units/mL 1mL IV final	☐ Heparin Sodium 10 units/mL 3mL IV final		tunneled Catheter:			
flush post normal saline flush flush post normal saline		flush	□ Heparin Sodium 100 units/mL 3-5mL IV final			
		flush post normal saline flush				
** May substitute Dextrose 5% in Water, or alternative	, for 0.9& Sodium Chloride, w	hen indicated due to inco	mpatibility with medications bring infused			
SIGNATURE						
We hereby authorize Talis Healthcare LLC to provide all supplies and additional services (nursing/patient training) required to provide and deliver the						
medicine as prescribed in this referral.						

To ensure payment by insurance carrier, please include supporting clinical documentation for specified ICD 10 Code, demographic, and insurance information along with faxed order. Initial appointment will be verified upon insurance approval.

Signature

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.

Prescriber